Skip to content

Author

A. Voors

We have 9 of 1,351 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Liver fibrosis in heart failure patients is associated with adverse outcomes, signs of congestion, and αv integrin-related processes: insights from BIOSTAT-CHF

Liver disease is common in heart failure (HF) and is associated with worse outcomes, although the pathophysiological mechanisms remain poorly understood. Previous studies suggest that liver fibrosis without steatosis carries a poorer prognosis in HF patients. We report the outcomes and clinical characteris...

M. Z. K. Tow, W. Ouwerkerk, M. Win et al. · 0 citations
Nov 2026

Abstract 6518: Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF

Background: The Kidney Failure Risk Equation (KFRE) is recommended in international guidelines for estimating the risk of kidney failure in patients with chronic kidney disease (CKD). The prognostic relevance of the KFRE has not been described in patients with heart failure and mildly reduced or preserved ejection f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Sep 2026

Prognostic value of epicardial and pericardial adipose tissue in patients with chronic heart failure

It is hypothesized that epicardial and pericardial adipose tissue (EAT and PAT) are easily obtainable on standard echocardiography and provide prognostic value in patients with HF and may serve as a valuable prognostic marker in chronic HF.

Y. Crum, D. van Veldhuisen, M. Lobeek et al. · 0 citations
Open access Jul 2026

Prevalence and clinical correlates of metabolic dysfunction-associated steatotic liver disease in heart failure

Abstract Background The nomenclature change from non-alcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) better encapsulates the associated metabolic milieu. While MASLD is associated with increased heart failure (HF) risk, characteristics and outcomes of MASLD in patients...

N. Chew, Chandramouli Chanchal, W. Tay et al. · 0 citations
Sep 2026

Implications of urinary albumin-to-creatinine ratio for subsequent kidney function decline and kidney-related outcomes in patients hospitalized for worsening heart failure: Insights from the JROADHF-NEXT registry.

BACKGROUND Albuminuria is a well-established marker of kidney damage. However, its association with subsequent kidney function and outcomes in patients with heart failure remains unclear. METHODS We utilized data from JROADHF-NEXT, a prospective, nationwide registry enrolling patients hospitalized for heart failure....

Y. Akama, Y. Singh, T. Nakade et al. · 0 citations
Open access Aug 2026

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial.

BACKGROUND The HFpEF-ABA score is a simple diagnostic tool developed to estimate the probability of heart failure with preserved ejection fraction (HFpEF) using age, body mass index, and history of atrial fibrillation. OBJECTIVES This study aims to evaluate the HFpEF-ABA score in patients with confirmed heart failure...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Sep 2026

Automated assessment of echocardiograms to aid diagnosis of heart failure with preserved ejection fraction

The HFA-PEFF and H2FPEF scores based on automated and manual echocardiographic analysis showed similar diagnostic accuracy, suggesting automated HFpEF diagnosis using deep learning analysis of echocardiograms is feasible.

C. Venema, M. Venner, A. Achten et al. · 1 citation
Review Open access Sep 2026

Body Composition in Heart Failure: A Phenotype-Informed Framework for Assessment and Management.

Body mass index (BMI) and waist-based anthropometric indices are widely used to estimate adiposity and cardiometabolic risk. Yet in established heart failure (HF), modestly higher BMI is associated with improved survival, while waist-based measures show a linear association with worse outcomes. This apparent discrepanc...

C. C. S. van der Hoef, J. T. ter Maaten, L. Meems et al. · 0 citations
Open access Sep 2026

Efficacy of Vericiguat by Background Guideline-Directed Medical Therapy in the VICTOR Trial.

In ambulatory patients with HFrEF receiving contemporary GDMT, it is not convincing evidence that the neutral effect of vericiguat on cardiovascular death or first HF hospitalization was modified by GDMT class, dose attainment, or overall intensity, in a cohort with very high background GDMT use and limited power for i...

Justin A. Ezekowitz, J. Butler, Derek Cyr et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.